Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2021-10-04 Earnings Release
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
PR - PHARMANUTRA third quarter sales
Earnings Release Classification · 1% confidence The document is an Italian regulatory announcement (Informazione Regolamentata) dated October 4, 2021. The subject ('Oggetto') is 'PR - PHARMANUTRA third quarter sales'. The text explicitly discusses sales volumes for the third quarter of 2021, comparing them to the previous year and confirming growth trends previously mentioned in the half-year report. This content—the initial announcement of periodical financial results (sales figures)—fits the definition of an Earnings Release (ER). Although it mentions 'Vedi allegato' (See attachment), the core content provided is the summary of the quarterly performance, making it the release itself rather than just a notice of publication (RPA). Since it focuses on quarterly sales highlights, ER is the most appropriate classification over the comprehensive Interim Report (IR). Q3 2021
2021-10-04 English
CS - PHARMANUTRA vendite terzo trimestre
Earnings Release Classification · 1% confidence The document is an official communication ('Informazione Regolamentata') from PHARMANUTRA dated October 4, 2021. The subject ('Oggetto') is 'CS - PHARMANUTRA vendite terzo trimestre' (Sales third quarter). The text explicitly discusses sales volumes for the third quarter (Q3) of 2021, comparing them to Q3 2020, and mentions the results confirm projections made during the presentation of the half-year report (Relazione Semestrale 2021). This content—a summary of key financial performance metrics for a specific interim period (Q3)—is characteristic of an Earnings Release (ER). It is not the full, comprehensive report (which would be an IR), nor is it a transcript (CT) or a management discussion (MDA), although it contains some commentary. Since it is an initial announcement of period results, ER is the most appropriate classification. Q3 2021
2021-10-04 Italian
PR - PHARMANUTRA - Half-Year Financial Report as of 30 June 2021
Report Publication Announcement Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata) dated September 13, 2021. The subject line explicitly states: 'PR - PHARMANUTRA - Half-Year Financial Report as of 30 June 2021'. The body of the text confirms that the 'Half – Year Financial Report as of 30th June 2021' is now available and directs the reader to where it can be found (registered office, website, storage mechanism). Since the document itself is an announcement stating the availability of the full report, and the report covers a period shorter than a year ('Half-Year'), it is primarily an announcement of an Interim/Quarterly Report. However, given the structure (a short announcement pointing to the full document), and the specific content being the release of a comprehensive financial report for a period shorter than a year, the most accurate classification for the *report itself* would be 'Interim / Quarterly Report' (IR). If this were purely the announcement wrapper, RPA would be considered, but the title and focus strongly suggest the core information relates to the release of the comprehensive half-year financials. Since the document explicitly mentions the 'Half-Year Financial Report', IR is the best fit for the underlying content being released, even if this specific text is the announcement wrapper. Given the length (4038 chars) and the explicit mention of the full report being available, it leans towards announcing the comprehensive report rather than just a brief update. Therefore, Interim / Quarterly Report (IR) is chosen.
2021-09-13 English
CS - PHARMANUTRA - Pubblicazione della Relazione Finanziaria Semestrale
Report Publication Announcement Classification · 1% confidence The document is a formal announcement from PHARMANUTRA S.P.A. dated September 13, 2021. The subject line ('Oggetto') explicitly states: 'CS - PHARMANUTRA - Pubblicazione della Relazione Finanziaria Semestrale' (Publication of the Semi-Annual Financial Report). The body confirms that the 'Relazione Finanziaria Semestrale al 30 giugno 2021' (Semi-Annual Financial Report as of June 30, 2021) is now available to the public. Since the document itself is short and its primary function is to announce the availability of a comprehensive report (the Semi-Annual Financial Report), it fits the definition of a Report Publication Announcement (RPA). The comprehensive report itself would likely be classified as an Interim / Quarterly Report (IR), but this document is the announcement of that report.
2021-09-13 Italian
PHARMANUTRA - Half-Year Financial Report as of 30 June 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM MANAGEMENT REPORT' and explicitly states it is for the six months ended 30 June 2021. It contains comprehensive financial data, including consolidated balance sheets, income statements, and cash flow statements, as well as management's discussion and analysis of the business performance. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2021
2021-09-13 English
PHARMANUTRA - Fascicolo completo relazione finanziaria semestrale 2021
Interim / Quarterly Report Classification · 1% confidence The document is a 'Relazione Finanziaria Semestrale' (Half-Yearly Financial Report) for PharmaNutra S.p.A. as of June 30, 2021. It contains comprehensive financial statements, including the consolidated balance sheet, income statement, and cash flow statement, as well as management's discussion and analysis. It is not an announcement or a summary, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-09-13 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.